<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
14.06.2019 08:29:58

Press Release: Novartis continues to innovate in -2-

to perform frequent monitoring of BCR-ABL transcript levels and complete

blood count with differential in order to detect possible loss of

remission. For patients who fail to achieve MMR after three months of

treatment re-initiation, BCR-ABL kinase domain mutation testing should

(Anzeige)Passende neue Barrier Reverse Convertibles

be performed.

Musculoskeletal pain, myalgia, pain in extremity, arthralgia, bone pain

and spinal pain may occur upon discontinuing treatment with Tasigna

within the framework of attempting treatment-free remission.

The most frequent Grade 3 or 4 adverse events are hematological

(neutropenia, thrombocytopenia, anemia) which are generally reversible

and usually managed by withholding Tasigna temporarily or dose

reduction. Chemistry panels, including electrolytes, lipid profile,

liver enzymes, and glucose should be checked prior to therapy and

periodically. Tasigna can cause increases in serum lipase. The most

frequent non-hematologic adverse events were rash, pruritus, nausea,

fatigue, headache, alopecia, myalgia, constipation and diarrhea.

Please see full Prescribing Information at http://www.tasigna.com/.

Disclaimer

This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995. Forward-looking statements can generally be identified by words

such as "potential," "can," "will," "plan," "expect," "anticipate,"

"look forward," "believe," "committed," "investigational," "pipeline,"

"launch," or similar terms, or by express or implied discussions

regarding potential marketing approvals, new indications or labeling for

the investigational or approved products described in this press release,

or regarding potential future revenues from such products. You should

not place undue reliance on these statements. Such forward-looking

statements are based on our current beliefs and expectations regarding

future events and are subject to significant known and unknown risks and

uncertainties. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual

results may vary materially from those set forth in the forward-looking

statements. There can be no guarantee that the investigational or

approved products described in this press release will be submitted or

approved for sale or for any additional indications or labeling in any

market, or at any particular time. Nor can there be any guarantee that

such products will be commercially successful in the future. In

particular, our expectations regarding such products could be affected

by, among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures and requirements for increased pricing transparency; our

ability to obtain or maintain proprietary intellectual property

protection; the particular prescribing preferences of physicians and

patients; general political and economic conditions; safety, quality or

manufacturing issues; potential or actual data security and data privacy

breaches, or disruptions of our information technology systems, and

other risks and factors referred to in Novartis AG's current Form 20-F

on file with the US Securities and Exchange Commission. Novartis is

providing the information in this press release as of this date and does

not undertake any obligation to update any forward-looking statements

contained in this press release as a result of new information, future

events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

1. David M. Ross, et al. Durability and impact on quality of life of

treatment-free remission (tfr) in patients with chronic myeloid leukemia

(cml) after stopping frontline (1l) nilotinib: ENESTfreedom 192-wk

results. Abstract# PF409. 24th Congress of the European Hematology

Association. June 13-16, Amsterdam, The Netherlands.

2. François-Xavier Mahon, et al. ENESTop 192-wk results: durability and

impact on quality of life of treatment-free remission (tfr) following

second-line (2l) nilotinib (nil) in patients (pts) with chronic myeloid

leukemia (cml). Abstract # PF411. 24th Congress of the European

Hematology Association. June 13-16, Amsterdam, The Netherlands.

3. Jorge Cortes, et al. Combination therapy using asciminib plus imatinib

(ima) in patients (pts) with chronic myeloid leukemia (cml): results from

a phase 1 study. Abstract # S883. 24th Congress of the European

Hematology Association. June 13-16, Amsterdam, The Netherlands.

4. Michael Mauro, et al. Combination of asciminib plus nilotinib (nil) or

dasatinib (das) in patients (pts) with chronic myeloid leukemia (cml):

results from a phase 1 study. Abstract # S884. 24th Congress of the

European Hematology Association. June 13-16, Amsterdam, The Netherlands.

# # #

Novartis Global External Communications

E-mail: media.relations@novartis.com

Antonio Ligi Michael Billings

Novartis Global External Communications Novartis Hematology Communications

+41 61 324 1374 (direct) +1 862 778 8656 (direct)

+41 79 723 3681 (mobile) +1 201 400 1854 (mobile)

antonio.ligi@novartis.com michael.billings@novartis.com

Eric Althoff

Novartis US External Communications

+ 1 646 438 4335

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Novartis Pharma AG Novartis Pharmaceuticals

Corporation

CH-4002 Basel Switzerland (c) 2019 Novartis 6/19 East Hanover, New Jersey

G-CML-1213520 07936-108

Media release (PDF): http://hugin.info/134323/R/2246066/887387.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

June 14, 2019 02:30 ET (06:30 GMT)